[S29] The consideration of the ideal form of PMDA's review reports as drug information —from the perspectives of the regulatory authorities, medical institutions, and industries—

1:20 PM - 1:25 PM JST(4:20 AM - 4:25 AM UTC)

[S29-1] Considering prospects of PMDA review reports

○Yasutsugu Nakano^1,2 (1. Japan Pharmaceutical Manufacturers Association, 2. Shionogi & Co., Ltd.)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.